Table of Contents Author Guidelines Submit a Manuscript
International Journal of Endocrinology
Volume 2014, Article ID 703696, 6 pages
http://dx.doi.org/10.1155/2014/703696
Research Article

Plasma Antimicrobial Peptide LL-37 Level Is Inversely Associated with HDL Cholesterol Level in Patients with Type 2 Diabetes Mellitus

1Division of Endocrinology, Metabolism and Nephrology, Department of Internal Medicine, School of Medicine, Keio University, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan
2Department of Internal Medicine, Saiseikai Central Hospital, 1-4-17 Mita, Minato-ku, Tokyo 108-0073, Japan
3Minami-Aoyama Home Clinic, 7-5-2 Minami Aoyama, Minato-ku, Tokyo 107-0062, Japan
4Department of Pathology, National Institute of Infectious Disease, 1-23-1 Toyama, Shinjuku-ku, Tokyo 162-0052, Japan

Received 7 January 2014; Revised 17 February 2014; Accepted 17 February 2014; Published 26 March 2014

Academic Editor: Faustino R. Pérez-López

Copyright © 2014 Shu Meguro et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Zasloff, “Fighting infections with vitamin D,” Nature Medicine, vol. 12, no. 4, pp. 388–390, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. M. Zasloff, “Antimicrobial peptides of multicellular organisms,” Nature, vol. 415, no. 6870, pp. 389–395, 2002. View at Publisher · View at Google Scholar · View at Scopus
  3. D. Vandamme, B. Landuyt, W. Luyten, and L. Schoofs, “A comprehensive summary of LL-37, the factotum human cathelicidin peptide,” Cellular Immunology, vol. 280, no. 1, pp. 22–35, 2012. View at Publisher · View at Google Scholar
  4. R. Bucki, K. Leszczyńska, A. Namiot, and W. Sokołowski, “Cathelicidin LL-37: a multitask antimicrobial peptide,” Archivum Immunologiae et Therapiae Experimentalis, vol. 58, no. 1, pp. 15–25, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. A. H. Lichtman, C. J. Binder, S. Tsimikas, and J. L. Witztum, “Adaptive immunity in atherogenesis: new insights and therapeutic approaches,” Journal of Clinical Investigation, vol. 123, no. 1, pp. 27–36, 2013. View at Publisher · View at Google Scholar
  6. K. Edfeldt, B. Agerberth, M. E. Rottenberg et al., “Involvement of the antimicrobial peptide LL-37 in human atherosclerosis,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 26, no. 7, pp. 1551–1557, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. C. D. Ciornei, H. Tapper, A. Bjartell, N. H. Sternby, and M. Bodelsson, “Human antimicrobial peptide LL-37 is present in atherosclerotic plaques and induces death of vascular smooth muscle cells: a laboratory study,” BMC Cardiovascular Disorders, vol. 6, article 49, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. Y. Döring, M. Drechsler, S. Wantha et al., “Lack of neutrophil-derived CRAMP reduces atherosclerosis in mice,” Circulation Research, vol. 110, no. 8, pp. 1052–1056, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. C. J. Nolan, P. Damm, and M. Prentki, “Type 2 diabetes across generations: from pathophysiology to prevention and management,” The Lancet, vol. 378, no. 9786, pp. 169–181, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. M. Stolar, “Glycemic control and complications in type 2 diabetes mellitus,” The American Journal of Medicine, vol. 123, no. 3, pp. S3–S11, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. T. Mazzone, A. Chait, and J. Plutzky, “Cardiovascular disease risk in type 2 diabetes mellitus: insights from mechanistic studies,” The Lancet, vol. 371, no. 9626, pp. 1800–1809, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. A. Kashiwagi, M. Kasuga, E. Araki et al., “International clinical harmonization of glycated hemoglobin in Japan: from Japan diabetes society to national glycohemoglobin standardization program values,” Journal of Diabetes Investigation, vol. 3, no. 1, pp. 39–40, 2012. View at Publisher · View at Google Scholar · View at Scopus
  13. S. Matsuo, E. Imai, M. Horio et al., “Revised equations for estimated GFR from serum creatinine in Japan,” The American Journal of Kidney Diseases, vol. 53, no. 6, pp. 982–992, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. D. Davis, T. Kern, and L. I. Rand, International Textbook of Diabetes Mellitus, Diabetic Retinopathy, John Wiley & Sons, Chichester, UK, 2nd edition, 1997.
  15. S. M. Haffner, S. Lehto, T. Rönnemaa, K. Pyörälä, and M. Laakso, “Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction,” The New England Journal of Medicine, vol. 339, no. 4, pp. 229–234, 1998. View at Publisher · View at Google Scholar · View at Scopus
  16. T. Nishimura, K. Nakajima, H. Kusuoka, A. Yamashina, and S. Nishimura, “Prognostic study of risk stratification among Japanese patients with ischemic heart disease using gated myocardial perfusion SPECT: J-ACCESS study,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 35, no. 2, pp. 319–328, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. S. Lehto, T. Rönnemaa, S. M. Haffner, K. Pyörälä, V. Kallio, and M. Laakso, “Dyslipidemia and hyperglycemia predict coronary heart disease events in middle-aged patients with NIDDM,” Diabetes, vol. 46, no. 8, pp. 1354–1359, 1997. View at Google Scholar · View at Scopus
  18. H. C. Gerstein, M. E. Miller, R. P. Byington et al., “Effects of intensive glucose lowering in type 2 diabetes,” The New England Journal of Medicine, vol. 358, no. 24, pp. 2545–2559, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. A. Patel, S. MacMahon, J. Chalmers et al., “Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes,” The New England Journal of Medicine, vol. 358, no. 24, pp. 2560–2572, 2008. View at Publisher · View at Google Scholar
  20. W. Duckworth, C. Abraira, T. Moritz et al., “Glucose control and vascular complications in veterans with type 2 diabetes,” The New England Journal of Medicine, vol. 360, no. 2, pp. 129–139, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. C. Cimminiello, “What intervention trials don't tell us: the residual risk in primary prevention,” Internal and Emergency Medicine, vol. 6, no. 1, supplement, pp. 53–60, 2011. View at Google Scholar · View at Scopus
  22. A. Zambon, “Residual cardiovascular risk in secondary prevention,” Internal and Emergency Medicine, vol. 6, no. 1, supplement, pp. 61–68, 2011. View at Google Scholar · View at Scopus
  23. G. G. Schwartz, A. G. Olsson, M. Abt et al., “Effects of dalcetrapib in patients with a recent acute coronary syndrome,” The New England Journal of Medicine, vol. 367, no. 22, pp. 2089–2099, 2012. View at Publisher · View at Google Scholar
  24. S. E. Nissen, J. Tardif, S. J. Nicholls et al., “Effect of torcetrapib on the progression of coronary atherosclerosis,” The New England Journal of Medicine, vol. 356, no. 13, pp. 1304–1316, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. P. J. Barter, M. Caulfield, M. Eriksson et al., “Effects of torcetrapib in patients at high risk for coronary events,” The New England Journal of Medicine, vol. 357, no. 21, pp. 2109–2122, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. H. B. Brewer Jr., “Clinical review: the evolving role of HDL in the treatment of high-risk patients with cardiovascular disease,” Journal of Clinical Endocrinology and Metabolism, vol. 96, no. 5, pp. 1246–1257, 2011. View at Publisher · View at Google Scholar · View at Scopus
  27. G. D. Norata, A. Pirillo, E. Ammirati, and A. L. Catapano, “Emerging role of high density lipoproteins as a player in the immune system,” Atherosclerosis, vol. 220, no. 1, pp. 11–21, 2012. View at Publisher · View at Google Scholar · View at Scopus
  28. M. G. Sorci-Thomas and M. J. Thomas, “High density lipoprotein biogenesis, cholesterol efflux, and immune cell function,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 32, no. 11, pp. 2561–2565, 2012. View at Publisher · View at Google Scholar
  29. P. M. Ridker, C. H. Hennekens, J. E. Buring, and N. Rifai, “C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women,” The New England Journal of Medicine, vol. 342, no. 12, pp. 836–843, 2000. View at Publisher · View at Google Scholar · View at Scopus
  30. J. Danesh, J. G. Wheeler, G. M. Hirschfield et al., “C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease,” The New England Journal of Medicine, vol. 350, no. 14, pp. 1387–1397, 2004. View at Publisher · View at Google Scholar · View at Scopus
  31. Emerging Risk Factors Collaboration, S. Kaptoge, E. di Angelantonio et al., “C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis,” The Lancet, vol. 375, no. 9709, pp. 132–140, 2010. View at Publisher · View at Google Scholar
  32. H. Arima, M. Kubo, K. Yonemoto et al., “High-sensitivity c-reactive protein and coronary heart disease in a general population of Japanese: the Hisayama study,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 28, no. 7, pp. 1385–1391, 2008. View at Publisher · View at Google Scholar · View at Scopus
  33. P. M. Ridker, E. Danielson, F. A. H. Fonseca et al., “Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein,” The New England Journal of Medicine, vol. 359, no. 21, pp. 2195–2207, 2008. View at Publisher · View at Google Scholar · View at Scopus
  34. P. M. Ridker, E. Danielson, F. A. Fonseca et al., “Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial,” The Lancet, vol. 373, no. 9670, pp. 1175–1182, 2009. View at Publisher · View at Google Scholar · View at Scopus
  35. Q. Wang, W. Zhang, H. Li et al., “Effects of 25-hydroxyvitamin D3 on cathelicidin production and antibacterial function of human oral keratinocytes,” Cell Immunology, vol. 283, no. 1-2, pp. 45–50, 2013. View at Publisher · View at Google Scholar
  36. H. B. Nguyen, B. Eshete, K. H. Lau, A. Sai, M. Villarin, and D. Baylink, “Serum 1, 25-dihydroxyvitamin D: an outcome prognosticator in human sepsis,” PLoS ONE, vol. 8, no. 5, Article ID e64348, 2013. View at Publisher · View at Google Scholar